HAEM5:Hairy cell leukaemia: Difference between revisions
| [unchecked revision] | [unchecked revision] |
Bailey.Glen (talk | contribs) No edit summary |
Bailey.Glen (talk | contribs) No edit summary |
||
| Line 4: | Line 4: | ||
{{Under Construction}} | {{Under Construction}} | ||
<blockquote class='blockedit'>{{Box-round|title=HAEM5 Conversion Notes|This page was converted to the new template on 2023- | <blockquote class='blockedit'>{{Box-round|title=HAEM5 Conversion Notes|This page was converted to the new template on 2023-12-04. The original page can be found at [[HAEM4:Hairy Cell Leukemia]]. | ||
}}</blockquote> | }}</blockquote> | ||
==Primary Author(s)*== | ==Primary Author(s)*== | ||
| Line 13: | Line 13: | ||
==Cancer Category / Type== | ==Cancer Category / Type== | ||
*[[Mature B-Cell Neoplasms|Mature B-Cell Neoplasm]] | *[[HAEM4:Mature B-Cell Neoplasms|Mature B-Cell Neoplasm]] | ||
==Cancer Sub-Classification / Subtype== | ==Cancer Sub-Classification / Subtype== | ||
| Line 192: | Line 192: | ||
|BRAF p.Val600Glu | |BRAF p.Val600Glu | ||
|Diagnostic | |Diagnostic | ||
|May be useful when immunophenotype is equivocal; Excludes [[ | |May be useful when immunophenotype is equivocal; Excludes [[HAEM5:Splenic B-cell lymphoma/leukaemia with prominent nucleoli|HCLv]] | ||
|- | |- | ||
|MAP2K1 | |MAP2K1 | ||
| Line 396: | Line 396: | ||
<sup>‡</sup>Specific mutations in these genes can be found in [https://www.cbioportal.org/ cBioPortal] and [https://cancer.sanger.ac.uk/cosmic COSMIC]. | <sup>‡</sup>Specific mutations in these genes can be found in [https://www.cbioportal.org/ cBioPortal] and [https://cancer.sanger.ac.uk/cosmic COSMIC]. | ||
'''*'''The WHO states that BRAF p.Val600Glu is detected in virtually all cases and notes that the classification of B-cell leukemias that are immunophenotypically and morphologically classified as HCL but lack BRAF activating mutations (but instead have MAP2K1 activating mutations and use the IGHV4-34 gene segment) is uncertain. These seem to be more similar molecularly and clinically to [[ | '''*'''The WHO states that BRAF p.Val600Glu is detected in virtually all cases and notes that the classification of B-cell leukemias that are immunophenotypically and morphologically classified as HCL but lack BRAF activating mutations (but instead have MAP2K1 activating mutations and use the IGHV4-34 gene segment) is uncertain. These seem to be more similar molecularly and clinically to [[HAEM5:Splenic B-cell lymphoma/leukaemia with prominent nucleoli|HCLv]]. | ||
*BRAF and MAP2K1 activating mutations are mutually exclusive | *BRAF and MAP2K1 activating mutations are mutually exclusive | ||
| Line 473: | Line 473: | ||
==Links== | ==Links== | ||
*[[ | *[[HAEM5:Splenic B-cell lymphoma/leukaemia with prominent nucleoli]] | ||
*[[Splenic | *[[HAEM5:Splenic diffuse red pulp small B-cell lymphoma]] | ||
==References== | ==References== | ||